Show simple item record

dc.contributor.authorMansoor, Was
dc.contributor.authorFerguson, S
dc.contributor.authorRoss, V
dc.contributor.authorTalbot, D
dc.date.accessioned2020-04-22T07:25:07Z
dc.date.available2020-04-22T07:25:07Z
dc.date.issued2020en
dc.identifier.citationManoharan P, Lamarca A, Navalkissoor S, Calero J, Chan PS, Julyan P, et al. Safety, tolerability and clinical implementation of 'ready-to-use' (68)gallium-DOTA0-Tyr3-octreotide ((68)Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). ESMO Open. 2020;5.en
dc.identifier.pmid32190050en
dc.identifier.doi10.1155/2020/9287536en
dc.identifier.urihttp://hdl.handle.net/10541/622903
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1155/2020/9287536en
dc.titleDiagnostic and management pathways for pulmonary carcinoid tumours in the United Kingdom: results from the National Lung Neuroendocrine Tumour Pathway Projecten
dc.typeArticleen
dc.contributor.departmentThe Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.en
dc.identifier.journalInternational Journal of Endocrinologyen
dc.description.noteen]
refterms.dateFOA2020-04-22T09:06:26Z


Files in this item

Thumbnail
Name:
32190050.pdf
Size:
1.349Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record